WeTrials
Active, not recruiting

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors

What is this study?

This study is testing a new anti-cancer drug called LP-184 for adults with advanced solid tumors, including certain types of lung, breast, pancreatic, and brain cancers. Researchers want to find the safest and most effective dose to help patients who have already tried standard treatments.

Who can participate?

You may be able to join if you are 18 or older, have a confirmed advanced solid tumor that has not responded to standard treatments, and are well enough to handle daily activities. Certain conditions, like active infections or recent treatments, may prevent you from participating.

What will happen?

Participants will receive the study drug through an intravenous infusion on Day 1 and Day 8 of every 21-day cycle, for at least two cycles. Doctors will closely monitor your safety, how your body processes the medicine, and how well the treatment works.

Where and when?

The study locations include sites in Arkansas, Indiana, and Kentucky in the United States. This study is currently active but is not looking for new participants at this time.

Key Points
  • 1Testing a new investigational cancer drug called LP-184
  • 2For adults with advanced solid tumors who need new options
  • 3Involves regular infusions and close health monitoring

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Solid TumorMetastatic Solid TumorGBMTNBC - Triple-Negative Breast CancerNSCLCPancreatic AdenocarcinomaDDR Gene Mutation

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.